Use of aspirin associates with longer primary patency of hemodialysis grafts.

Published

Journal Article

Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions of each component are unknown. Here, we analyzed whether use of aspirin at baseline associated with primary unassisted graft patency among participants in a randomized trial that compared ERDP/ASA and placebo in newly created grafts. We used Cox proportional hazards regression, adjusting for prespecified baseline comorbidities and covariates. Of all participants, 43% reported use of aspirin at baseline; of these, 82% remained on nonstudy aspirin (i.e., excluding ERDP/ASA) at 1 year. After 1 year of follow-up, the incidence of primary unassisted patency among participants using aspirin at baseline was 30% (95% CI: 24 to 35%) and among those not using aspirin was 23% (95% CI: 18 to 27%). Use of aspirin at baseline associated with a dose-dependent prolongation of primary unassisted graft patency that approached statistical significance (adjusted HR, 0.83; 95% CI: 0.68 to 1.01; P=0.06). Use of aspirin at baseline did not associate with prolongation of cumulative graft patency or participant survival. In conclusion, use of aspirin associates with a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to that observed for ERDP/ASA.

Full Text

Duke Authors

Cited Authors

  • Dixon, BS; Beck, GJ; Dember, LM; Vazquez, MA; Greenberg, A; Delmez, JA; Allon, M; Himmelfarb, J; Hu, B; Greene, T; Radeva, MK; Davidson, IJ; Ikizler, TA; Braden, GL; Lawson, JH; Cotton, JR; Kusek, JW; Feldman, HI; Dialysis Access Consortium (DAC) Study Group,

Published Date

  • April 2011

Published In

Volume / Issue

  • 22 / 4

Start / End Page

  • 773 - 781

PubMed ID

  • 21415156

Pubmed Central ID

  • 21415156

Electronic International Standard Serial Number (EISSN)

  • 1533-3450

Digital Object Identifier (DOI)

  • 10.1681/ASN.2010060582

Language

  • eng

Conference Location

  • United States